vs
Apellis Pharmaceuticals, Inc.（APLS）与HOPE BANCORP INC（HOPE）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是HOPE BANCORP INC的1.4倍（$199.9M vs $141.0M），HOPE BANCORP INC净利率更高（20.9% vs -29.5%，领先50.4%），HOPE BANCORP INC同比增速更快（21.0% vs -5.9%），过去两年HOPE BANCORP INC的营收复合增速更高（9.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
希望银行（Bank of Hope）是总部位于美国洛杉矶的银行机构，前身为1980年12月30日成立的威尔希尔银行，核心服务群体为韩裔美国人社区，在当地族裔金融服务领域拥有长期的运营经验。
APLS vs HOPE — 直观对比
营收规模更大
APLS
是对方的1.4倍
$141.0M
营收增速更快
HOPE
高出27.0%
-5.9%
净利率更高
HOPE
高出50.4%
-29.5%
两年增速更快
HOPE
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $141.0M |
| 净利润 | $-59.0M | $29.5M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 20.9% |
| 营收同比 | -5.9% | 21.0% |
| 净利润同比 | -62.2% | -14.3% |
| 每股收益（稀释后） | $-0.40 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSHOPE
| Q1 26 | — | $141.0M | ||
| Q4 25 | $199.9M | $145.8M | ||
| Q3 25 | $458.6M | $141.9M | ||
| Q2 25 | $178.5M | $94.5M | ||
| Q1 25 | $166.8M | $116.5M | ||
| Q4 24 | $212.5M | $118.0M | ||
| Q3 24 | $196.8M | $116.6M | ||
| Q2 24 | $199.7M | $116.9M |
净利润APLSHOPE
| Q1 26 | — | $29.5M | ||
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $30.8M | ||
| Q2 25 | $-42.2M | $-24.8M | ||
| Q1 25 | $-92.2M | $21.1M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $24.2M | ||
| Q2 24 | $-37.7M | $25.3M |
营业利润率APLSHOPE
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 26.8% | ||
| Q3 25 | 48.7% | 25.6% | ||
| Q2 25 | -18.6% | -27.6% | ||
| Q1 25 | -50.0% | 23.9% | ||
| Q4 24 | -12.3% | 25.8% | ||
| Q3 24 | -24.0% | 27.5% | ||
| Q2 24 | -14.7% | 29.5% |
净利率APLSHOPE
| Q1 26 | — | 20.9% | ||
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 21.7% | ||
| Q2 25 | -23.6% | -26.2% | ||
| Q1 25 | -55.3% | 18.1% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 20.7% | ||
| Q2 24 | -18.9% | 21.6% |
每股收益（稀释后）APLSHOPE
| Q1 26 | — | $0.23 | ||
| Q4 25 | $-0.40 | $0.27 | ||
| Q3 25 | $1.67 | $0.24 | ||
| Q2 25 | $-0.33 | $-0.19 | ||
| Q1 25 | $-0.74 | $0.17 | ||
| Q4 24 | $-0.30 | $0.20 | ||
| Q3 24 | $-0.46 | $0.20 | ||
| Q2 24 | $-0.30 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $2.3B |
| 总资产 | $1.1B | $18.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSHOPE
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
股东权益APLSHOPE
| Q1 26 | — | $2.3B | ||
| Q4 25 | $370.1M | $2.3B | ||
| Q3 25 | $401.2M | $2.3B | ||
| Q2 25 | $156.3M | $2.2B | ||
| Q1 25 | $164.2M | $2.2B | ||
| Q4 24 | $228.5M | $2.1B | ||
| Q3 24 | $237.1M | $2.2B | ||
| Q2 24 | $264.3M | $2.1B |
总资产APLSHOPE
| Q1 26 | — | $18.7B | ||
| Q4 25 | $1.1B | $18.5B | ||
| Q3 25 | $1.1B | $18.5B | ||
| Q2 25 | $821.4M | $18.5B | ||
| Q1 25 | $807.3M | $17.1B | ||
| Q4 24 | $885.1M | $17.1B | ||
| Q3 24 | $901.9M | $17.4B | ||
| Q2 24 | $904.5M | $17.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSHOPE
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $164.5M | ||
| Q3 25 | $108.5M | $51.7M | ||
| Q2 25 | $4.4M | $9.4M | ||
| Q1 25 | $-53.4M | $26.7M | ||
| Q4 24 | $19.4M | $116.7M | ||
| Q3 24 | $34.1M | $63.0M | ||
| Q2 24 | $-8.3M | $-25.6M |
自由现金流APLSHOPE
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $151.5M | ||
| Q3 25 | $108.3M | $47.2M | ||
| Q2 25 | $4.4M | $6.9M | ||
| Q1 25 | $-53.4M | $24.0M | ||
| Q4 24 | $19.3M | $106.9M | ||
| Q3 24 | — | $60.1M | ||
| Q2 24 | $-8.4M | $-28.1M |
自由现金流率APLSHOPE
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 103.9% | ||
| Q3 25 | 23.6% | 33.2% | ||
| Q2 25 | 2.5% | 7.3% | ||
| Q1 25 | -32.0% | 20.6% | ||
| Q4 24 | 9.1% | 90.6% | ||
| Q3 24 | — | 51.6% | ||
| Q2 24 | -4.2% | -24.0% |
资本支出强度APLSHOPE
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 9.0% | ||
| Q3 25 | 0.0% | 3.2% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.0% | 2.3% | ||
| Q4 24 | 0.0% | 8.3% | ||
| Q3 24 | 0.0% | 2.5% | ||
| Q2 24 | 0.0% | 2.2% |
现金转化率APLSHOPE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.68× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.61× | ||
| Q2 24 | — | -1.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HOPE
暂无分部数据
